MOLN: Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan molecularpartners.com

Molecular Partners AG utilizes proprietary DARPin protein engineering to develop multi-target oncology drugs. The team of Swiss biologists operates with a high degree of research autonomy. Quarterly EPS progress demonstrates earnings per share dynamics, while the 4.90 mark reflects the latest data. The company's production capacities are functioning stably, undergoing scheduled modernization of synthesis equipment.

molecularpartners.com (MOLN) - Wutah bathi EPS kuartalan saka 04.07.2022 nganti 14.11.2026

Rincian analitis perusahaan molecularpartners.com (MOLN)

- nilai pasar lan prakiraan target analis:

Bagan rega Molecular Partners AG|MOLN - Bagan tingkat prakiraan

- informasi kapitalisasi pasar:

Nilai pasar Molecular Partners|MOLN - Nilai Total Perusahaan

- data kapitalisasi buku:

Nilai Buku saben Saham Molecular Partners|MOLN - Kapitalisasi Buku|Rasio Kapitalisasi marang Aset Bersih molecularpartners.com|MOLN - Aset Agregat Bisnis

- indikator beban utang lan likuiditas:

Total Utang marang Modal Molecular Partners AG|MOLN - Kewajiban jangka dawa marang ekuitas|Utang jangka cendhak marang ekuitas molecularpartners.com|MOLN - Utang kumulatif perusahaan|Rasio utang marang kapitalisasi buku Molecular Partners AG|MOLN - Silihan lan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Molecular Partners|Likuiditas cepet molecularpartners.com

- indikator bathi lan kelipatan valuasi:

MOLN - Asil keuangan resik|Bathi sing dikarepake Molecular Partners AG|MOLN - Koefisien rega marang bathi|Rega marang bathi mangsa ngarep Molecular Partners Ltd|MOLN - Rega marang bathi kanthi panyesuaian wutah|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Molecular Partners|MOLN - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|Bathi resik saben saham (EPS TTM) Molecular Partners|MOLN - Bathi resik saben siji saham sajrone rolas wulan pungkasan|Wutah bathi EPS kuartalan molecularpartners.com|MOLN - Wutah bathi resik saben saham ing taun iki|Prakiraan wutah bathi saben saham kanggo taun ngarep Molecular Partners AG

- rincian pendapatan lan dodolan:

MOLN - Pendapatan lan volume dodolan|Prakiraan pendapatan perusahaan Molecular Partners|MOLN - Rasio rega marang pendapatan|Multiplikator Forward P/S Molecular Partners

Analisis komprehensif perusahaan:Molecular Partners AG

Quarterly EPS growth measures the rate of change in net income per share, reflecting the efficiency of capital generation. This metric allows investors to filter out market noise and assess the issuer's actual operational resilience. By analyzing earnings per share dynamics on a quarterly basis, one can identify hidden risks of overpaying for an asset. For Molecular Partners AG (MOLN), this trend confirms the monetization of unique DARPin proteins. Patent protection and inelastic demand provide the company with significant pricing power.

Karo sapa Molecular Partners AG saingan

Geron (GERN) - Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan|Dinamika bathi resik saben saham taun-ka-taun sajrone rolas wulan pungkasan NBTX (Nanobiotix Group)|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan Bicycle Therapeutics|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan CTMX|Wutah bathi EPS kuartalan CATX|Wutah bathi EPS kuartalan Genelux Corp (GNLX)|Oncolytics Biotech - Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan|Kacepetan wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan LSTA (Lisata)|Moleculin Biotech, Inc. - Wutah bathi EPS kuartalan|Dinamika bathi resik saben saham taun-ka-taun sajrone rolas wulan pungkasan GRTX|Molecular Templates Corporation (MTEM) - Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan